<DOC>
	<DOC>NCT01089062</DOC>
	<brief_summary>Compare the acute effects and tolerability of Dihydroergotamine Mesylate (DHE) delivered by Oral Inhalation (MAP0004) versus by intravenous (IV) infusion in healthy adult volunteers.</brief_summary>
	<brief_title>Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure</brief_title>
	<detailed_description />
	<mesh_term>Dihydroergotamine</mesh_term>
	<criteria>1. Able to provide a signed, executed written informed consent 2. Healthy nonsmoking adult volunteers: Male or Female subjects 18 to 45 years old 3. Female subjects who are practicing adequate contraception 4. Stable cardiac status 5. Normal hemoglobin values 6. Normal Echocardiogram 7. Normal or not clinically significant 12lead Electrocardiogram 8. Demonstrated ability to properly use the TempoÂ® Inhaler 9. Subject has not donated blood in the last 56 days 1. Contraindication to dihydroergotamine mesylate (DHE) 2. Use of any excluded concomitant medications within the 10 days prior to Visit 1 3. History of hemiplegic or basilar migraine 4. Participation in another investigational trial during the 30 days prior to Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Healthy volunteers</keyword>
</DOC>